Mathieu Andrianoely

Mathieu Andrianoely

Auto-generated profile, based on publicly available information

Mathieu Andrianoely

IHU Liryc, Electrophysiology and Heart Modelling Institute, INSERM U1045, University of Bordeaux, Bordeaux, France

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2026 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
OWOscar Werner
Oscar Werner
MFMarc Fila
Marc Fila
FHFanchon Herman
Fanchon Herman
MAMarion Audié
Marion Audié
JHJérôme Harambat
Jérôme Harambat
PAPascal Amedro
Pascal Amedro
Key Points: Children with CKD exhibit markedly lower cardiopulmonary fitness with an absolute maximal oxygen uptake deficit of 10 ml/kg per minute compared with reference values. More than half of the patients show impaired fitness as early as CKD stage 3, highlighting early functional vulnerability. Maximal oxygen uptake is independently associated with modifiable parameters commonly targeted by rehabilitation, supporting tailored intervention strategies. Background: Children with CKD are at high cardiovascular risk, yet cardiopulmonary fitness is rarely assessed in routine care. Maximal oxygen uptake (VO 2 max) is a powerful prognostic marker, and Z -score–based evaluations may improve early risk stratification. Methods: In this prospective multicenter study, children aged 6–17 years with CKD stages 2–5 (Kidney Disease Improving Global Outcome) underwent standardized cardiopulmonary exercise testing (CPET). VO 2 max was expressed as Z -scores using contemporary pediatric reference values. Impaired fitness was defined as VO 2 max Z -score <–1.64. Multivariable linear regression was used to identify independent determinants of VO 2 max. Results: Among 88 enrolled patients (mean age 12±4 years, 67% male), 77 completed a valid CPET. Mean VO 2 max Z -score was −1.8±2.1, corresponding to 33.5±9.2 ml/kg per minute, that is, an absolute lowering of approximately 10 ml/kg per minute compared with age-matched and sex-matched reference values. Overall, 57% had impaired fitness. VO 2 max was progressively lower across higher CKD stages ( P < 0.001 ). In multivariable analysis, higher VO 2 max was independently associated with higher hemoglobin concentration, better pulmonary function (forced expiratory volume in 1 s), better ventilatory efficiency (VE/VCO 2 slope), and higher ventilatory anaerobic threshold, explaining 77% of VO 2 max variability. Conclusions: Cardiopulmonary fitness is markedly lower in children with CKD, with a clear stage-dependent decline that is already evident at early disease stages. The magnitude of VO 2 max impairment is substantial and related to potentially modifiable clinical and functional factors, supporting early CPET-based screening and the development of targeted, multidisciplinary rehabilitation in pediatric CKD. Clinical Trial registry name and registration number: Clinicaltrials.gov identifier NCT04897672 and Montpellier University Hospital Institutional Review Board (IRB 202100852).

7 July 2026 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
PAPascal Amedro
Pascal Amedro
MAMathieu Andrianoely
Mathieu Andrianoely
PGPauline Gohier
Pauline Gohier
JLJustine Leroux
Justine Leroux
NANathalie Aladjidi
Nathalie Aladjidi
JGJulien Gotchac
Julien Gotchac
Background: Barth syndrome (BTHS) is a rare X-linked mitochondrial disorder characterized by cardiomyopathy, neutropenia, and skeletal myopathy. Elamipretide is a mitochondria-targeting peptide that stabilizes cardiolipin and improves mitochondrial function. While use of this treatment in infants with BTHS has been reported in the United States, no cases have been described outside the US or in older children. Case presentation: We report the first case of a preschool-aged child with genetically confirmed BTHS and advanced heart failure, who was treated with elamipretide under a compassionate use program approved by the French Drug Administration (ANSM). At treatment initiation, this 5-year-old patient presented with severe left ventricular dysfunction (LVEF = 20%) and moderate-to-severe mitral regurgitation. He was dependent on gastrostomy feeding and had been listed for heart transplantation. Subcutaneous elamipretide (10 mg/day) was initiated alongside maximal conventional heart failure therapy. Over six months, LVEF improved to 50%, mitral regurgitation decreased to mild, Ross class improved from IV to I, and substantial gains were observed in functional capacity, nutritional status, and health-related quality of life (HRQoL). The patient returned to full-time school and remained temporarily suspended from the transplant list. Treatment was generally well tolerated. One transient, non-serious episode of abdominal pain with moderate pancreatic enzyme elevation occurred, which resolved without treatment discontinuation. Conclusions: This case suggests that elamipretide may improve cardiac function, exercise tolerance, nutrition, and HRQoL in preschool-aged pediatric BTHS patients, potentially delaying the need for transplantation. Broader pediatric evaluation is warranted. Further strategies, such as youth-tailored hybrid cardiac rehabilitation programs, could complement pharmacological therapy and further optimize outcomes in this population.

29 April 2026 in European Journal of Cardiovascular Nursing
Verified
Journal Article
Open access
PDF file
JMJohan Moreau
Johan Moreau
CNCaroline Neyraud
Caroline Neyraud
HHHelena Huguet
Helena Huguet
MAMathieu Andrianoely
Mathieu Andrianoely
HRHuguette Romieu
Huguette Romieu
PAPascal Amedro
Pascal Amedro
Aims: Despite significant medical advances in recent decades, cardiopulmonary fitness decreases faster in youth with congenital heart disease (CHD) than in healthy peers, resulting in impaired health-related quality of life (HRQoL) and increased cardiovascular risk. Apart from cardiac rehabilitation, non-pharmacological preventive interventions have been scarcely evaluated in this population. Sophrology, a mind–body method involving dynamic relaxation in full awareness, breathing exercises, and imagination, has demonstrated benefits for mental health and well-being. This multicentre randomized controlled trial evaluated the impact of a remote sophrology programme on cardiopulmonary fitness and HRQoL in youth with CHD. Methods and results: A total of 200 13-to-25-year-old CHD patients were randomly assigned to either the intervention (i.e. eight remote individual sophrology sessions) or the standard of care. The primary outcome was the change in maximum oxygen uptake (VO2max) measured by cardiopulmonary exercise testing from baseline to 12 months. Secondary outcomes included HRQoL and mental health assessments. No significant VO2max group difference was observed [mean difference −0.11; 95% confidence interval (CI) −2.02; 1.79; P = 0.91]. The HRQoL ‘Mental Component Summary’, ‘Mental Health’, and ‘Vitality’ SF-36 scores increased in the young adult intervention subgroup (18–25 years) by 8.98 (95% CI 2.73; 15.23, P < 0.01, effect size 0.84), 14.49 (95% CI 3.17; 25.81, P = 0.01, effect size 0.74), and 15.75 (95% CI 3.97; 27.53, P < 0.01, effect size 0.78) points, respectively. Conclusion: The remote sophrology programme did not improve cardiopulmonary fitness, but significantly enhanced HRQoL in young adults with CHD. Integrating mind–body practices into preventive cardiology programmes should be further evaluated. Registration: Clinicaltrials.gov: NCT03999320.

21 July 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
MAMathieu Andrianoely
Mathieu Andrianoely
ADArielle Desir
Arielle Desir
HHHelena Huguet
Helena Huguet
MPMarie-Christine PICOT
Marie-Christine PICOT
MAMarion Audie
Marion Audie
CJCecile Jore
Cecile Jore
Background: The QUALIREHAB (Cardiac Rehabilitation in Youth With Congenital Heart Disease) trial demonstrated the efficacy of a hybrid cardiac rehabilitation model in adolescents and young adults with congenital heart disease. This post hoc mixed‐methods study aimed to identify baseline predictors of clinical improvement and to characterize key components supporting implementation and scalability. Methods: Seventy participants aged 13 to 25 years from the intervention arm were analyzed. Clinical improvement was defined as a clinically meaningful increase in cardiopulmonary fitness (increase in peak oxygen uptake ≥3.5 mL/kg per min) or health‐related quality of life (Pediatric Quality of Life Inventory increase ≥4.3 points). Multivariable logistic regression models identified predictors of clinical improvement. Semistructured interviews with patients and health care professionals explored experiences, barriers, and implementation mechanisms. Results: The absence of prior cardiac surgery or interventional catheterization was independently associated with short‐term improvement in peak oxygen uptake. At 1 year, male sex and lower baseline ventilatory anaerobic threshold were associated with greater peak oxygen uptake improvement. Lower baseline ventilatory anaerobic threshold was also the only predictor of clinically meaningful health‐related quality of life improvement. Qualitative findings highlighted the accessibility and acceptability of the hybrid model but underscored the need for higher‐intensity and more varied exercise modalities, integrated digital tools, continuous psychological support, family involvement, and structured postrehabilitation follow‐up to sustain long‐term benefits. Conclusions: Among treated participants, male sex, absence of prior cardiac surgery, and marked baseline deconditioning were associated with greater clinical improvement, supporting a shift from standardized toward tailored cardiac rehabilitation in congenital heart disease. By addressing key logistical and psychosocial barriers, this scalable framework offers a pragmatic model for routine care implementation and may be transferable to other pediatric chronic conditions. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03690518.